By inhibiting miR-26a/b, EGFR activates the expression of hepatocyte growth factor, which is considered a tumor promoter 79, increasing the likelihood of liver metastasis in patients with GC and validating the “soil and seed” hypothesis of the tumor metastasis mechanism that is popular in clinical practice. The gene discussed is HGF; the disease is gastric cancer.